scholarly journals A divergent route towards single-chemical entity triazine dendrimers with opportunities for structural diversity

2007 ◽  
Vol 31 (7) ◽  
pp. 1283 ◽  
Author(s):  
Hannah Crampton ◽  
Emily Hollink ◽  
Lisa M. Perez ◽  
Eric E. Simanek
Keyword(s):  
Structural Diversity ◽  
Chemical Entity ◽  
Single Chemical

scholarly journals Chiral Polythiophenes: Part I: Syntheses of Monomeric Precursors

Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4205
Author(s):  
Dorota Krasowska ◽  
Rafał Karpowicz ◽  
Józef Drabowicz
Keyword(s):  
Thin Layer ◽  
Chemical Entity ◽  
Single Chemical ◽  
Synthetic Approaches

The purpose of this mini-review is to comprehensively present the synthetic approaches used for the preparation of non-racemic mono- and multi-substituted thiophenes, which, in turn, can be applied as precursors for the synthesis of chiral polythiophenes isolated as a single chemical entity or having supramolecular thin-layer architectures.

scholarly journals Scaffold hybridization strategy towards potent hydroxamate-based inhibitors ofFlaviviridaeviruses andTrypanosomaspecies

MedChemComm ◽  
2019 ◽  
Vol 10 (6) ◽  
pp. 991-1006 ◽  
Author(s):  
Erofili Giannakopoulou ◽  
Vasiliki Pardali ◽  
Efseveia Frakolaki ◽  
Vasileios Siozos ◽  
Vassilios Myrianthopoulos ◽  
...  
Keyword(s):  
Chemical Entity ◽  
Design And Synthesis ◽  
Single Chemical

Design and synthesis of potent inhibitors with dual activity by successfully merging two distinct scaffolds into a single chemical entity.

Endoperoxide Carbonyl Falcipain 2/3 Inhibitor Hybrids: Toward Combination Chemotherapy of Malaria through a Single Chemical Entity

2010 ◽  
Vol 53 (22) ◽  
pp. 8202-8206 ◽  
Author(s):  
Peter Gibbons ◽  
Edite Verissimo ◽  
Nuna C. Araujo ◽  
Victoria Barton ◽  
Gemma L. Nixon ◽  
...  
Keyword(s):  
Combination Chemotherapy ◽  
Chemical Entity ◽  
Single Chemical

Single Chemical Entity Legal Highs: Assessing the Risk for Long Term Harm

2012 ◽  
Vol 5 (4) ◽  
pp. 304-319 ◽  
Author(s):  
Carolyn B. McNabb ◽  
Bruce R. Russell ◽  
Daniele Caprioli ◽  
David J. Nutt ◽  
Simon Gibbons ◽  
...  
Keyword(s):  
Chemical Entity ◽  
Legal Highs ◽  
Single Chemical

Multitargeted drugs discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity

2011 ◽  
Vol 21 (9) ◽  
pp. 2655-2658 ◽  
Author(s):  
Maria Laura Bolognesi ◽  
Manuela Bartolini ◽  
Andrea Tarozzi ◽  
Fabiana Morroni ◽  
Federica Lizzi ◽  
...  
Keyword(s):  
Chemical Entity ◽  
Single Chemical

Metal-, and Organocatalyst-Free One-Pot Assembly of Chiral Aza-Tricyclic Molecules: Creating Six Contiguous Stereocenters from 2-D-Structures and an Amino Acid

2020 ◽  
Author(s):  
Dung Do
Keyword(s):  
Amino Acid ◽  
Chemical Space ◽  
Structural Diversity ◽  
Therapeutic Agents ◽  
Chiral Molecules ◽  
One Pot ◽  
Complex Molecules ◽  
Chiral Catalyst ◽  
Chiral Complex ◽  
Free Process

<p>Chiral molecules with their defined 3-D structures are of paramount importance for the study of chemical biology and drug discovery. Having rich structural diversity and unique stereoisomerism, chiral molecules offer a large chemical space that can be explored for the design of new therapeutic agents.<sup>1</sup> Practically, chiral architectures are usually prepared from organometallic and organocatalytic processes where a transition metal or an organocatalyst is tailor-made for desired reactions. As a result, developing a method that enables rapid assembly of chiral complex molecules under metal- and organocatalyst-free condition represents a daunting challenge. Here we developed a straightforward route to create a chiral 3-D structure from 2-D structures and an amino acid without any chiral catalyst. The center of this research is the design of a <a>special chiral spiroimidazolidinone cyclohexadienone intermediate</a>, a merger of a chiral reactive substrate with multiple nucleophillic/electrophillic sites and a transient organocatalyst. <a>This unique substrate-catalyst (“subcatalyst”) dual role of the intermediate enhances </a><a>the coordinational proximity of the chiral substrate and catalyst</a> in the key Aza-Michael/Michael cascade resulting in a substantial steric discrimination and an excellent overall diastereoselectivity. Whereas the “subcatalyst” (hidden catalyst) is not present in the reaction’s initial components, which renders a chiral catalyst-free process, it is strategically produced to promote sequential self-catalyzed reactions. The success of this methodology will pave the way for many efficient preparations of chiral complex molecules and aid for the quest to create next generation of therapeutic agents.</p>

Sign in / Sign up

Export Citation Format

Share Document